CClinicalTrials.gg
CompletedNCT03688724DPOCUSUpdated Jan 21, 2022

Perioperative Diaphragm Point of Care Ultrasound

An observational study in Postoperative Pulmonary Complications, Diaphragm and Brachial Plexus Block, sponsored by Hospital General Universitario de Valencia. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-21.

Sponsored by Hospital General Universitario de Valencia · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
65
Ages
18 Years and older
Sex
All
01

Study summary

It is a prospective observational study of a cohort of patients who underwent brachial plexus blockage above the clavicle, and in which diaphragmatic function is observed in both hemidiaphragms by ultrasound (using Diaphragm Thickening Fraction), which allows to obtain the real incidence of Hemidiaphragm palsy in these patients, and estimate the perioperative evolution of both hemidiaphragms.

Hemidiaphragm palsy after brachial plexus block above the clavicle (BPBAC) is frequent, but few patients develop postoperative pulmonary complications (PPC). Little attention has been paid to the contralateral hemidiaphragm as part of the global diaphragmatic function. After BPBAC, global diaphragm function reduces due to ipsilateral hemidiaphragm reduction, but less than expected due to the increase in the contralateral hemidiaphragm function. As a part of the diaphragm function, the contralateral hemidiaphragm function plays a relevant role in the appearance of PPC.

Read the detailed description

INTRODUCTION Shoulder surgery is known to be a particularly painful stimulus. Perioperative analgesia using brachial plexus block by injection above the clavicle (BPBAC) for shoulder surgery is the standard of care 1,2.

Up to date, ipsilateral diaphragmatic paresis after BPBAC is still very frequent, but few patients develop postoperative pulmonary complications (PPC), and most of them are mild8. There is much concern in avoiding ipsilateral hemidiaphragmatic paralysis to reduce PPC. Little attention has been paid to the contralateral diaphragm and the global diaphragmatic function formed by both hemidiaphragms (the ipsilateral and the contralateral to the BPBAC).

A meticulous study of perioperative diaphragm evolution is needed to answer why some patients after BPBAC develop PPC and others do not.

OUTCOMES The primary objective was to examine the evolution of perioperative hemidiaphragm function with ultrasound (ipsilateral and contralateral) when using BPBAC following shoulder surgery.

the hypothesis is that despite frequent acute ipsilateral hemidiaphragm paralysis after BPBAC, the contralateral hemidiaphragm function increases and preserves global diaphragmatic function in most patients.

METHODS A prospective observational cohort study evaluating perioperative (preoperative and postoperative) diaphragm point-of-care ultrasound (D-POCUS) at an academic tertiary hospital in Spain. Adults undergoing shoulder surgery with planned BPBAC (ISB or SCB) will be eligible for inclusion. Patients planned for not receive BPBAC for any reason will be exclude.

Thickening diaphragm fraction (TF) and diaphragm excursion (DE) were measured in both hemidiaphragms before BPBAC (at the preoperative time) and within 30 min after surgery (at the postoperative time, at least 1 hour after BPBAC).

All measures will be repeated three times in each patient and by the same member of the research team to reduce intra-observer and inter-observer variability. In addition, he will be blinded to the side on which the BPBAC will be performed.

TF was calculated using the following formula: TF = (Tdi-Tde)/Tde x100 (%). TF ipsilateral was the TF measured in the hemidiaphragm ipsilateral to the BPBAC. TF contralateral was the TF measured in the hemidiaphragm contralateral to the BPBAC. TFglobal was the sum of both hemidiaphragm TF to reflect the global diaphragm function. It was calculated using the following formula: (TF Global = (TF ipsilateral + TF contralateral). DE was measured in mm.

Baseline characteristics of participants were collected, including age, gender, comorbidities, respiratory rate (RR), basal SpO2 (Oxygen saturation measured by pulse oximeter), respiratory symptoms, and ARISCAT scale . also data were collect during perioperative, related to BPBAC (loco-regional technique, local anesthetic, concentration, volume of injection); related to intraoperative management (hypnotics, morphic and blocking neuromuscular agents used); and related to postoperative (Train-Of-Four(TOF) scale, visual analog scale (VAS) Pain, RR, SpO2, fraction of inspired oxygen (FiO2), SpO2/FiO2, existence of postoperative pulmonary complications (PPC) ). PPC is defined as the occurrence of dyspnea, tachypnea (RR >20% of preoperative RR), SpO2 \<90%, or SpO2/FiO2 \<315.

Statistical Analyses Continuous variables will be reported as medians with their interquartile range [IQR] or means with standard deviations (SD) where applicable, and categorical variables as counts and percentages. Group comparisons of continuous variables will be made using the Student t-test or Mann-Whitney U test, or Wilcoxon rank-sum test as appropriate. Chi-square test, Fisher exact test, and Kruskal-Wallis test will be used where appropriate for categorical variables. Analyses will be performed using IBM SPSS Statistics for Windows, Version 24.0 (IBM Corp, Armonk, NY).

SAMPLE SIZE

The sample size was calculated using Gpower 3.1. An effect size of 0.48 was calculated based on the difference between two dependent means (matched pairs) obtained on previous pilot study data. The occurrence of TFcontralateral variation before and after BPBAC was 12±30. A sample size of 59 patients was required to detect a 20% of TFcontralateral variation with 95% power and a two-sided alpha of 0.05. an increase of 10% on sample size was applied.

TOTAL n= 65 patients.

02

Conditions studied

  • Postoperative Pulmonary Complications
  • Diaphragm
  • Brachial Plexus Block
03

In context

Lead sponsor

Hospital General Universitario de Valencia is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients scheduled for upper limb surgery

Inclusion criteria

  • Patients scheduled for any type of surgery that requires a supraclavicular or interscalene block.

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years
  • No locoregional blockade over the clavicular for any reason, allergy to local anesthetics, coagulopathy, clinical reason.
  • Rejection to enter the observational study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
65 participants (actual)
Target follow-up
2 Days
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Contralateral Diaphragm function change

    Thickening fraction (%) change of contralateral hemidiaphragm Before-After Brachial plexus Block

    Time frame: day of surgery (1 hour before surgery starts and 1 hour after surgery ends)

Secondary outcomes

  1. Ipsilateral Diaphragm function change

    Thickening fraction (%) of ipsilateral hemidiaphragm to BPBAC

    Time frame: day of surgery (1hour before surgery starts and 1hour after surgery ends)

  2. Incidence of Postoperative Pulmonary Complications

    we consider PPC (Dyspnea, oxygen saturation below 92%,PO2/FiO2\<300, need for reintubation, high respiratory rate\>22)

    Time frame: postoperative 30 min after surgery at PACU(post anesthesia care unit)

  3. Incidence of contralateral hemidiaphragm increase after BPBAC.

    we consider Contralateral hemidiaphragm increase any Thickening Fraction at postoperative \>Thickening Fraction at preoperative.

    Time frame: POSTOPERATIVE 30 min after surgery at PACU (post anesthesia care unit)

07

Study locations

1 site
  • Hospital General Universitario de Valencia
    Valencia, 46003, Spain
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03688724
Lead sponsor
Hospital General Universitario de Valencia
Responsible party
Lucas Rovira (Principal Investigator, Hospital General Universitario de Valencia) — Principal investigator
First posted
Sep 28, 2018
Start date
Oct 15, 2018
Primary completion
Mar 5, 2021
Completion
May 1, 2021
Last update
Jan 21, 2022

Study contacts

Lucas Rovira, PhD
principal investigator · HGUV

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion